Sanofi’s New Patient Support Updates in 2021

Sanofi is continuing its commitment to ensure affordable access to medications and has now expanded affordable access to its insulin+GLP1RA combination Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL. New for 2021 on the insulins front: Toujeo Max SoloStar pen (insulin glargine injection) 300 Units/mL has been added to the Insulins Valyou Savings Program.

Over the last several years, Sanofi’s Insulins Valyou Savings Program has continued to evolve to better meet the needs of uninsured patients who need access to Sanofi medications. In 2021, this evolution expanded even further to include the Toujeo Max SoloStar pen. Now, the Insulins Valyou Savings Program offers eligible patients one or multiple Sanofi insulins, up to ten 10mL vials or packs of SoloStar pens or up to five packs of Max SoloStar pens, for $99 per month. This offer is valid for 1 fill per month, and you must fill all Sanofi insulin prescriptions at the same time, together each month.

Similarly, Sanofi has added a new cash offer for Soliqua 100/33® (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL. While separate from the Insulins Valyou Savings Program, Sanofi has created another way to support people who are using this medicine, but don’t have insurance. This offer can be accessed via the Soliqua 100/33 copay card and allows eligible patients to pay as little as $99 per box of pens, for up to two boxes of pens per 30-day supply. You can call 1-855-262-5295 between 8AM and 8PM ET, Monday through Friday (excluding holidays) to speak to a live specialist to understand your specific options with Soliqua 100/33.

In addition to these updates, here is a recap of Sanofi’s existing offerings:

Sanofi believes that any person living with diabetes regardless of income level or insurance coverage should be able to afford their insulin. To this end, Sanofi has provided patient support programs over the past several years to help meet each person’s needs.

More Information on Sanofi Diabetes Patient Support Programs:
For People Living with Diabetes who have Commercial Health Insurance
Every person with commercial health insurance, regardless of income level, is eligible for Sanofi co-pay assistance programs, where a majority of eligible patients pay between $0 to $10 per month for their Sanofi diabetes medicines. The savings cards for these medications can be accessed in just a few moments after signing up:

• Adlyxin® (lixisenatide) injection
• Apidra® (insulin glulisine injection) 100 Units/mL
• Lantus® (insulin glargine injection) 100 Units/mL
• Toujeo® (insulin glargine injection) 300 Units/mL
• Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL

For People Living with Diabetes who have No Health Insurance
The Insulins Valyou Savings Program is available for all uninsured patients, regardless of income level. Eligible patients can purchase one or multiple Sanofi insulins (Lantus, Toujeo, Admelog, and Apidra) for a fixed price of $99 per month, for up to ten boxes of SoloStar pens and/or 10 mL vials or 5 boxes of Toujeo Max SoloStar pens.

Soliqua 100/33’s cash offer also allows uninsured people to pay $99 per box of pens, for up to two boxes of pens for a 30-day supply. This offer can be accessed via the Soliqua 100/33 copay card.

For People Living with Diabetes who may need free insulin due to low or middle-income status
Sanofi provides diabetes medications at no cost to qualified low- and middle-income patients who are uninsured or functionally uninsured through the patient assistance component of the Sanofi Patient Connection program. This program includes all Sanofi diabetes products. Some people facing an unexpected financial hardship may be eligible for a one-time, immediate month’s supply of their Sanofi medicine as they wait for their patient assistance application to process.

To help those who have been impacted as a result of COVID-19, Sanofi implemented temporary changes to this program. These changes will remain in place so long as patients continue to remain impacted by COVID-19

• Those already participating in the patient assistance program can make an early reorder of their prescription(s) to ensure they have a 90-day supply.
• Sanofi has expanded acceptable documentation for proof of income to additionally accommodate those experiencing a job loss, furlough, or reduced hours in the pandemic
• Sanofi has extended the Temporary Patient Assistance Program (TPAP) from 90 days to 180 days. The TPAP is for patients who meet all the eligibility criteria of the patient assistance program but may be Medicaid eligible and are awaiting a response letter.

For People Living with Diabetes and who have Medicare Insurance.
Sanofi has volunteered to join the Centers for Medicare and Medicaid Services (CMS) Part D Senior Savings Model or insulin demo plan because it is consistent with our commitment of improving access and affordability for people living with diabetes. Patients who enroll in a participating plan would have their insulin covered and pay $35 Out of Pocket for a 30-day script of insulin throughout the year. Sanofi diabetes medications participating in the model include Lantus, Toujeo, Apidra, Admelog, and Soliqua 100/33.

Every patient has unique circumstances, and Sanofi has live support specialists who can be reached at (855) 984-6302 to answer individual patient’s questions and navigate their unique situation to find the best resources and programs to help lower their out-of-pocket costs.

To learn more about Sanofi’s patient support programs, please visit https://www.teamingupfordiabetes.com/sanofidiabetes-savings-program.

 

Sanofi is a 2021 National Strategic Partner of DiabetesSisters. DiabetesSisters shares information they provide that is useful to our community; however, the relationship does not influence the decisions or opinions of DiabetesSisters, its governing board or staff.